{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T09:10:38Z","timestamp":1790413838962,"version":"4.1.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":7104,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2003,7]]},"DOI":"10.1046\/j.1538-7836.2003.00264.x","type":"journal-article","created":{"date-parts":[[2003,6,20]],"date-time":"2003-06-20T11:45:15Z","timestamp":1056109515000},"page":"1371-1380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":140,"title":["Estrogens, progestogens and thrombosis"],"prefix":"10.1016","volume":"1","author":[{"given":"F.R.","family":"Rosendaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Van Hylckama Vlieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.C.","family":"Tanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.M.","family":"Helmerhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0010","series-title":"Cardiovascular Disease and Steroid Hormone Contraception.","year":"1998"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0015","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1001\/archinte.162.17.1954","article-title":"Hormone replacement therapy and associated risk of stroke in postmenopausal women","volume":"162","author":"Lemaitre","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0020","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jama.288.8.980","article-title":"Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study","volume":"288","author":"Pradhan","year":"2002","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0025","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1046\/j.1471-0528.2002.02214.x","article-title":"Patterns of use of hormone replacement therapy in one million women in Britain, 1996\u20132000","volume":"109","year":"2002","journal-title":"BJOG"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0030","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0140-6736(61)91061-3","article-title":"Pulmonary embolism","volume":"ii","author":"Jordan","year":"1961","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0035","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/bmj.2.5313.1191-a","article-title":"Parietal lesions and Enavid","volume":"ii","author":"Lorentz","year":"1962","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0140-6736(63)91117-6","article-title":"Coronary thrombosis and Conovid","volume":"i","author":"Boyce","year":"1963","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.1973.03230060030009","article-title":"The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group","volume":"226","year":"1973","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2265.1997.2601068.x","article-title":"Mortality and morbidity in transsexual subjects treated with cross-sex hormones","volume":"47","author":"Van Kesteren","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0055","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(96)07113-9","article-title":"Risk of venous thromboembolism in users of hormone replacement therapy","volume":"348","author":"Daly","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0060","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","article-title":"Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens","volume":"348","author":"Jick","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(96)07308-4","article-title":"Prospective study of exogenous hormones and risk of pulmonary embolism in women","volume":"348","author":"Grodstein","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0075","series-title":"Phlogose und Thrombose im Gef\u00e4\u00dfsystem. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin.","author":"Virchow","year":"1856"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0080","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1055\/s-0038-1657542","article-title":"Thrombophilia as a multigenic disorder","volume":"78","author":"Seligsohn","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0085","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(98)10266-0","article-title":"Venous thrombosis: a multicausal disease","volume":"353","author":"Rosendaal","year":"1999","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0090","series-title":"Progestins and Antiprogestins in Clinical Practice","first-page":"101","article-title":"Pharmacology of progestins. 17-alpha-hydroxyprogesterone derivatives and progestins of the first and second generation","author":"Henzl","year":"2000"},{"issue":"Suppl. 4","key":"10.1046\/j.1538-7836.2003.00264.x_bb0095","first-page":"2","article-title":"The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea","volume":"69","author":"Van Vloten","year":"2002","journal-title":"Cutis"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0010-7824(93)90118-Q","article-title":"Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles","volume":"48","author":"Kuhnz","year":"1993","journal-title":"Contraception"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00016347909157227","article-title":"The development and evaluation of an ovulation inhibitor (DIAne) containing an antiandrogen","volume":"88","author":"Lachnit-Fixson","year":"1979","journal-title":"Acta Obstet Gynecol Scand Suppl"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0110","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1749-6632.1995.tb31386.x","article-title":"Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity","volume":"761","author":"Muhn","year":"1995","journal-title":"Ann NY Acad Sci"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0115","first-page":"1816","article-title":"Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism","volume":"80","author":"Oelkers","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0120","first-page":"267","article-title":"Oral contraception and thromboembolic disease","volume":"13","year":"1967","journal-title":"J R Coll General Pract"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/bmj.2.5599.199","article-title":"Investigation of relation between use of oral contraceptives and thromboembolic disease","volume":"i","author":"Vessey","year":"1968","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.2.5658.651","article-title":"Investigation of relation between use of oral contraceptives and thromboembolic disease: a further report","volume":"ii","author":"Vessey","year":"1969","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/oxfordjournals.aje.a121082","article-title":"Thromboembolism and oral contraceptives: an epidemiological case-control study","volume":"90","author":"Sartwell","year":"1969","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0140","first-page":"1399","article-title":"Boston Collaborative Drug Surveillance Program. Oral contraceptives and venous thromboembolic disease, surgically confirmed gall bladder disease and breast tumours","volume":"i","year":"1973","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0145","first-page":"299","article-title":"Oral contraceptives and nonfatal vascular disease \u2013 recent experience","volume":"59","author":"Porter","year":"1982","journal-title":"Obstet Gynecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0150","first-page":"393","article-title":"Oral contraceptives, venous thrombosis, and varicose veins","volume":"28","year":"1978","journal-title":"J R Coll General Pract"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0155","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/bmj.292.6519.526","article-title":"Oral contraceptives and venous thromboembolism: findings in a large prospective study","volume":"292","author":"Vessey","year":"1986","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0160","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2796.1995.tb00896.x","article-title":"Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties","volume":"238","author":"Koster","year":"1995","journal-title":"J Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0165","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(94)90286-0","article-title":"Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation","volume":"344","author":"Vandenbroucke","year":"1994","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ije\/21.1.48","article-title":"Risk factors for fatal venous thromboembolism in young women: a case-control study","volume":"21","author":"Thorogood","year":"1992","journal-title":"Int J Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0175","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0180","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/01443619509015499","article-title":"The risk of venous thromboembolism associated with low-oestrogen oral contraceptives","volume":"15","author":"Farmer","year":"1995","journal-title":"J Obst Gynecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0185","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.321.7270.1190","article-title":"Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis","volume":"321","author":"Jick","year":"2000","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0190","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(96)12215-7","article-title":"Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis","volume":"349","author":"Brandjes","year":"1997","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.160.1.49","article-title":"Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects","volume":"160","author":"Bloemenkamp","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0200","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(99)01257-X","article-title":"Venous thromboembolism among new users of different oral contraceptives","volume":"354","author":"Herings","year":"1999","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0205","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/0002-9378(93)90685-C","article-title":"A randomized trial of three oral contraceptives: comparison of bleeding patterns by contraceptive types and steroid levels","volume":"168","author":"Saleh","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0210","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/oxfordjournals.aje.a115799","article-title":"Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease","volume":"133","author":"Gerstman","year":"1991","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0215","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0220","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0225","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0230","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/bmj.323.7305.131","article-title":"Third generation oral contraceptives and risk of venous thrombosis: meta-analysis","volume":"323","author":"Kemmeren","year":"2001","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0235","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(01)06522-9","article-title":"Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives","volume":"358","author":"Vasilakis-Scaramozza","year":"2001","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0240","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/bmj.324.7342.869","article-title":"Dutch GPs warned against new contraceptive pill","volume":"324","author":"Sheldon","year":"2002","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0245","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1055\/s-0037-1613379","article-title":"Obesity: risk of venous thrombosis and the interaction with coagulation factors and oral contraceptive use","volume":"89","author":"Abdollahi","year":"2003","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0255","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1055\/s-0037-1614442","article-title":"Incidence of venous thromboembolism in families with inherited thrombophilia","volume":"81","author":"Simioni","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0260","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood.V92.7.2353","article-title":"Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families","volume":"92","author":"Martinelli","year":"1998","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0265","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.V85.6.1504.bloodjournal8561504","article-title":"High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance)","volume":"85","author":"Rosendaal","year":"1995","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0270","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1046\/j.1365-2141.1996.5712013.x","article-title":"Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden","volume":"93","author":"Rintelen","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0275","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.ATV.19.3.700","article-title":"Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis","volume":"19","author":"Martinelli","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0280","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1182\/blood.V88.10.3698.bloodjournal88103698","article-title":"A common genetic variation in the 3\u2032-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis","volume":"88","author":"Poort","year":"1996","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0285","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0290","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V95.12.3678.012k45_3678_3682","article-title":"High levels of factor IX increase the risk of venous thrombosis","volume":"95","author":"Van Hylckama Vlieg","year":"2000","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0295","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0300","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1055\/s-0037-1615956","article-title":"Factor X levels, polymorphisms in the promoter region of factor X and the risk of venous thrombosis","volume":"85","author":"De Visser","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0305","article-title":"Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis","volume":"1","author":"Van Hylckma Vlieg","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0310","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bmj.2.5965.241","article-title":"Myocardial infarction in young women with special reference to oral contraceptive practice","volume":"2","author":"Mann","year":"1975","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0315","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/oxfordjournals.aje.a112874","article-title":"Oral contraceptive use in relation to nonfatal myocardial infarction","volume":"111","author":"Rosenberg","year":"1980","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0320","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(79)91205-4","article-title":"Oral-contraceptive use in relation to myocardial infarction","volume":"i","author":"Shapiro","year":"1979","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0325","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1001\/jama.1978.03290230040022","article-title":"Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors","volume":"240","author":"Jick","year":"1978","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0330","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-89-1-58","article-title":"Oral contraceptives and nonfatal stroke in healthy young women","volume":"89","author":"Jick","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0335","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.1978.03280410045016","article-title":"Oral contraceptives and nonfatal myocardial infarction","volume":"239","author":"Jick","year":"1978","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0340","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM198109103051104","article-title":"Oral contraceptives and cardiovascular disease (first of two parts)","volume":"305","author":"Stadel","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0345","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1056\/NEJM198109173051205","article-title":"Oral contraceptives and cardiovascular disease (second of two parts)","volume":"305","author":"Stadel","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0350","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S0140-6736(97)02358-1","article-title":"Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0355","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(95)12393-8","article-title":"Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0360","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.1538-7836.2003.00079.x","article-title":"The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women","volume":"1","author":"Van Den Bosch","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0365","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.STR.0000015345.61324.3F","article-title":"Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke","volume":"33","author":"Kemmeren","year":"2002","journal-title":"Stroke"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0370","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa003216","article-title":"Oral contraceptives and the risk of myocardial infarction","volume":"345","author":"Tanis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0375","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0380","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(96)91334-3","article-title":"Risk of acute myocardial infarction and low-dose combined oral contraceptives","volume":"347","author":"Jick","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0385","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0010-7824(97)00118-2","article-title":"The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women","volume":"56","author":"Lewis","year":"1997","journal-title":"Contraception"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0390","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/bmj.318.7198.1579","article-title":"Oral contraceptives and myocardial infarction: results of the MICA case-control study","volume":"318","author":"Dunn","year":"1999","journal-title":"Br Med J"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0395","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/01.CIR.98.11.1058","article-title":"Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies","volume":"98","author":"Sidney","year":"1998","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0400","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood.V89.8.2817","article-title":"Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women","volume":"89","author":"Rosendaal","year":"1997","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0405","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1182\/blood.V90.5.1747","article-title":"A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women","volume":"90","author":"Rosendaal","year":"1997","journal-title":"Blood"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0410","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1161\/01.CIR.97.11.1037","article-title":"Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A","volume":"97","author":"Doggen","year":"1998","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0415","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1161\/01.CIR.0000051465.94572.D0","article-title":"No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age","volume":"107","year":"2003","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0420","doi-asserted-by":"crossref","unstructured":"MacLennan A, Lester S, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2001:CD002978.","DOI":"10.1002\/14651858.CD002978"},{"issue":"Suppl. 1","key":"10.1046\/j.1538-7836.2003.00264.x_bb0425","first-page":"82","article-title":"Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial results","volume":"47","author":"Watts","year":"2002","journal-title":"J Reprod Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0430","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1001\/jama.286.7.815","article-title":"Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial","volume":"286","author":"Villareal","year":"2001","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0435","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/humupd\/6.5.419","article-title":"Prevention of postmenopausal osteoporosis with oestrogen replacement therapy and associated compounds: update on clinical trials since 1995","volume":"6","author":"Doren","year":"2000","journal-title":"Hum Reprod Update"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0440","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(79)90640-8","article-title":"Post-menopausal oestrogens protect against fractures of hip and distal radius. A case-control study","volume":"2","author":"Hutchinson","year":"1979","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0445","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM198011203032102","article-title":"Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen","volume":"303","author":"Weiss","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0450","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jama.288.1.58","article-title":"Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Hulley","year":"2002","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0455","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJM198510243131703","article-title":"A prospective study of postmenopausal estrogen therapy and coronary heart disease","volume":"313","author":"Stampfer","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0460","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archinte.1993.00410120009002","article-title":"A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women","volume":"153","author":"Psaty","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0465","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.1983.03330310033022","article-title":"Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study","volume":"249","author":"Bush","year":"1983","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0470","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(81)92138-3","article-title":"Menopausal oestrogen therapy and protection from death from ischaemic heart disease","volume":"i","author":"Ross","year":"1981","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0475","first-page":"277","article-title":"Estrogen replacement therapy I: a 10-year prospective study in the relationship to osteoporosis","volume":"53","author":"Nachtigall","year":"1979","journal-title":"Obstet Gynecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0480","first-page":"1021","article-title":"A review of postmenopausal hormone therapy recommendations: potential for selection bias","volume":"82","author":"Hemminki","year":"1993","journal-title":"Obstet Gynecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0485","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0895-4356(93)90068-C","article-title":"Selection to postmenopausal therapy by women's characteristics","volume":"46","author":"Hemminki","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0490","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/bmj.308.6939.1268","article-title":"Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?","volume":"308","author":"Posthuma","year":"1994","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0495","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(96)24041-3","article-title":"Case-control study of venous thromboembolism risk in users of hormone replacement therapy","volume":"348","author":"Daly","year":"1996","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0500","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/oxfordjournals.aje.a009461","article-title":"Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe","volume":"147","author":"Varas Lorenzo","year":"1998","journal-title":"Am J Epidemiol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0505","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bmj.314.7083.796","article-title":"Hormone replacement therapy and risk of venous thromboembolism: population based case-control study","volume":"314","author":"Perez Gutthann","year":"1997","journal-title":"BMJ"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0510","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1001\/jama.1997.03550060053030","article-title":"Venous thromboembolic events associated with hormone replacement therapy","volume":"278","author":"Grady","year":"1997","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0515","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-132-9-200005020-00002","article-title":"Postmenopausal hormone therapy increases risk for venous thromboembolic disease","volume":"132","author":"Grady","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0520","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1055\/s-0037-1614363","article-title":"Hormone replacement therapy with estradiol and risk of venous thromboembolism \u2013 a population-based case-control study","volume":"82","author":"H\u00f8ibraaten","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0525","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1055\/s-0037-1613857","article-title":"Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45\u201364 years: relationships to hormone replacement therapy","volume":"83","author":"Lowe","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0530","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.ATV.0000018301.91721.94","article-title":"Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease","volume":"22","author":"Herrington","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0535","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1055\/s-0037-1614156","article-title":"Increased risk of recurrent venous thromboembolism during hormone replacement therapy \u2013 results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)","volume":"84","author":"H\u00f8ibraaten","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0540","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0545","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/jama.288.1.49","article-title":"Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen\/progestin Replacement Study follow-up (HERS II)","volume":"288","author":"Grady","year":"2002","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0550","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(02)12001-0","article-title":"Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0555","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jama.285.7.906","article-title":"Hormone replacement therapy, prothrombotic mutations, and the risk of incident non-fatal myocardial infarction","volume":"285","author":"Psaty","year":"2001","journal-title":"JAMA"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0560","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/01.ATV.0000019853.06725.5A","article-title":"Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women","volume":"22","author":"Lemaitre","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0565","doi-asserted-by":"crossref","unstructured":"Reiner AP, Heckbert SH, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM. Genetic variants of coagulation factor XIII, post-menopausal estrogen therapy, and risk of non-fatal myocardial infarction. Blood 2002; 27 Nov (epub ahead of print).","DOI":"10.1182\/blood-2002-07-2308"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0570","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1055\/s-0038-1649849","article-title":"Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity","volume":"74","author":"Scarabin","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0575","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1055\/s-0038-1650651","article-title":"Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives","volume":"76","author":"Quehenberger","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0580","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1471-0528.1991.tb15364.x","article-title":"Task force on oral contraceptives: A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations","volume":"98","year":"1991","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0585","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0140-6736(77)90888-1","article-title":"Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen","volume":"ii","author":"Meade","year":"1977","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0590","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2141.1995.tb05323.x","article-title":"Resistance to activated protein C in healthy women taking oral contraceptives","volume":"91","author":"Olivieri","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0595","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1161\/01.ATV.20.5.1404","article-title":"Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis","volume":"20","author":"Teede","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0600","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-0037-1615889","article-title":"Effects of hormone replacement therapy on coagulation, fibrinolysis, and thrombosis risk in postmenopausal women","volume":"82","author":"Koh","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0605","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/01.CIR.100.7.717","article-title":"Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen\/Progestin Interventions (PEPI) Study","volume":"100","author":"Cushman","year":"1999","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0610","first-page":"347","article-title":"The haemostatic balance","volume":"2","author":"\u00c5strup","year":"1958","journal-title":"Thromb Diath Haemorrh (Stutt)"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0615","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1055\/s-0038-1653788","article-title":"Sensitivity to activated protein C; influence of oral contraceptives and sex","volume":"73","author":"Henkens","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0620","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(99)06092-4","article-title":"Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study","volume":"354","author":"Rosing","year":"1999","journal-title":"Lancet"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0625","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1055\/s-0037-1613958","article-title":"Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study","volume":"84","author":"Middeldorp","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0630","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0037-1613960","article-title":"A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways","volume":"84","author":"Tans","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0635","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0037-1613959","article-title":"Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives","volume":"84","author":"Meijers","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0640","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-2141.1997.192707.x","article-title":"Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives","volume":"97","author":"Rosing","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0645","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1055\/s-0037-1612973","article-title":"Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation","volume":"87","author":"Kemmeren","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0650","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1161\/hc2901.092200","article-title":"Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association","volume":"104","author":"Mosca","year":"2001","journal-title":"Circulation"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0655","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1046\/j.0007-1048.2002.03356.x","article-title":"Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis","volume":"116","author":"Rosendaal","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1046\/j.1538-7836.2003.00264.x_bb0660","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2105\/AJPH.78.8.961","article-title":"Odd man out: a graphical approach to meta-analysis","volume":"78","author":"Walker","year":"1988","journal-title":"Am J Public Health"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1538-7836.2003.00264.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622150853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622150853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1538-7836.2003.00264.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:27:43Z","timestamp":1761532063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622150853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":131,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["S1538783622150853"],"URL":"https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00264.x","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2003,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estrogens, progestogens and thrombosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00264.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}